Sofetabart mipitecan received FDA breakthrough therapy designation for platinum-resistant ovarian cancer after prior ...
Recent advancements include targeted agents, immunotherapy, and fertility-sparing surgeries for patients with advanced ...
Shares of Corcept Therapeutics CORT were up 13.7% on Jan. 22, after the company announced that the phase III ROSELLA study, ...
Eli Lilly and Company LLY announced that the FDA has granted a Breakthrough Therapy designation to its novel folate receptor alpha (FRα) antibody-drug conjugate (ADC), sofetabart mipitecan (LY4170156) ...
Clinical Trials Arena on MSN
ImmunityBio’s glioblastoma regimen boosts survival in mid-stage study
As of 22 January, 19 of the 23 patients who have received treatment are still alive, with the longest evaluable survival ...
MedPage Today on MSN
Meat Intake and Ulcerative Colitis; AI for Bowel Prep; Is Liver Steatosis a Disease?
News and commentary from the world of gastroenterology and hepatology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results